Press release

Infant Bacterial Therapeutics (IBT) to Present Results of “The Connection Study” at PAS 2025 in Honolulu

Infant Bacterial Therapeutics (IBT) is pleased to announce that results from its pivotal Phase III trial, “The Connection Study,” will be presented at the Pediatric Academic Societies (PAS) 2025 Annual Meeting in Honolulu, Hawaii, on Saturday, April 26, 2025. Both the oral and poster presentations will take place at the Hawaii Convention Center and will be delivered by Prof. Josef Neu, Principal Investigator of the study and Professor of Pediatrics at the University of Florida.

The PAS 2025 Meeting, held from April 24–28, is a premier international forum for pediatric researchers, clinicians, and educators. IBT’s presentations will spotlight findings from its investigational therapeutic IBP-9414, a live biotherapeutic product designed to prevent necrotizing enterocolitis (NEC) and reduce all-cause mortality in preterm infants.

Presentation Details

Oral Presentation

Title: Effects of IBP-9414, a Live Biotherapeutic Product, on NEC, Time to Full Enteral Feeding, and Mortality in Very Low Birth Weight Infants: Results from The Connection Study
Presenter: Prof. Josef Neu, Principal Investigator, University of Florida
Date & Time: Saturday, April 26, 2025 – 7:00 AM to 8:30 AM HST
Location: Convention Center: Kalākaua Ballroom A (Level 4)

Poster Presentation

Title: Effects of IBP-9414 vs Placebo on Time to Reach Sustained Full Enteral Feeding in Very Low Birth Weight (VLBW) Infants: Results from The Connection Study
Presenter: Prof. Josef Neu, Principal Investigator, University of Florida
Date & Time: Saturday, April 26, 2025 – 2:30 PM to 4:45 PM HST
Location: Exhibit Hall, Hawaii Convention Center

About “The Connection Study”

The Connection Study is the largest randomized, double-blind, parallel-group, placebo-controlled trial to date evaluating the efficacy and safety of IBP-9414 in premature infants (birth weight 500–1500g) for the prevention of necrotizing enterocolitis (NEC) — a life-threatening condition in neonates.

For more information about IBT and The Connection Study, please visit www.ibtherapeutics.com. Details about the PAS 2025 Meeting can be found at www.pas-meeting.org.

About Us
Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in Stockholm. The company’s Class B shares are since September 10, 2018, listed on Nasdaq Stockholm (IBTB).

IBT is a pharmaceutical company whose purpose is to develop and commercialize drugs for diseases affecting premature babies. During the 12 years of drug development IBT has gained unique expertise in the field of drugs using live bacteria as active substances. This is a key competitive factor for our development programs.

IBT's main focus is the drug candidate IBP-9414, a formulated bacterial strain naturally found in human breast milk. IBP-9414, is expected to be the first product in the new class of biologics called "Live Biotherapeutic Products" for premature infants. The drug development of IBP-9414 is currently in its final stages for this important product for premature babies.

The portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP-1016, for the treatment of gastroschisis, a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs. IBP-1118 to prevent retinopathy of prematurity (ROP), one of the leading causes of blindness in premature babies, and IBP-1122 to eliminate vancomycin-resistant enterococci (VRE), which cause antibiotic-resistant hospital infections.

Through the development of these drugs, IBT can address medical needs where no sufficient treatments are available.